S'abonner

Stool-based Xpert MTB/RIF Ultra assay as a tool for detecting pulmonary tuberculosis in children with abnormal chest imaging: A prospective cohort study - 19/01/21

Doi : 10.1016/j.jinf.2020.10.036 
Xu-hui Liu a, b, Lu Xia a, Bin Song c, Heng Wang d, Xue-qin Qian a, Jian-hao Wei a, Tao Li a, Xiu-hong Xi a, Yuan-lin Song b, Shan-qun Li b, Douglas B. Lowrie a, Xiao-yong Fan a, e, f, , Shui-hua Lu a, e, f,
a Shanghai Public Health Clinical Center, Fudan University, Shanghai 201508, China 
b Shanghai Zhongshan Hospital, Fudan University, Shanghai, China 
c Wuhan Jinyintan Hospital, Wuhan, China 
d Guiyang Pulmonary Hospital, Guiyang, China 
e Wenzhou Medical University, Wenzhou, China 
f TB Center, Shanghai Emerging and Re-emerging Institute, 2901, Caolang Rd, Jinshan, Shanghai 201508, China 

Corresponding authors at: Shanghai Public Health Clinical Center, Fudan University, Shanghai 201508, China.Shanghai Public Health Clinical CenterFudan UniversityShanghai201508China

Highlights

Young children with pulmonary TB swallow sputum, in which Mycobacteria. tuberculosis could be detected from stool samples. Detecting pediatric pulmonary tuberculosis by stool Xpert MTB/RIF (Xpert) assay was reported, but the sensitivity was relatively lower than respiratory tract samples (RTS) and inconsistent in publications. The Xpert Ultra assay (Ultra) was designed to improve the sensitivity of Xpert, and was validated in previous studies. This study aimed to evaluate the value of stool-based Ultra assay in paediatric pulmonary TB (PTB). To overcome the bias introduced from heterogeneity in inclusion criteria, sample processing, and clinical definition, researchers performed a head-to-head comparison between assays, and the results were parallelly assessed against culture and composite reference standard.
Children under 5 years old were enrolled and well evaluated in this study. These populations are more likely to benefit from this technique but rarely evaluated. According to this study, the stool-based Xpert MTB/RIF Ultra test showed substantial agreement with respiratory tract sample test for PTB. This test may take the place of respiratory tests in resource-limited context, particularly in young children not able to expectorate.
The stool-based molecular tests were promising for the detection of PTB. However, this study unveiled some limitations of this technique, including more trace positive and potential false positive, which are less likely to appear in Xpert test. Impacts from these limitations should be assessed in further studies.

Le texte complet de cet article est disponible en PDF.

Summary

Objectives

To evaluate the diagnostic efficacy of stool-based Xpert MTB/RIF Ultra assay versus other assays for the detection of paediatric pulmonary tuberculosis (PTB).

Methods

A prospective head-to-head comparative study was conducted from Dec 2017 to May 2019 in Shanghai Public Health Clinical Centre. Samples were collected from children (< 15 years) with abnormal chest imaging (X-ray or CT scan) results for the following tests: Ultra on stool sample (Ultra-Stool), Ultra on respiratory tract sample (Ultra-RTS), Xpert MTB/RIF assay (Xpert) on RTS (Xpert-RTS), acid-fast bacilli smear on RTS (AFB-RTS), and Mycobacterium tuberculosis (Mtb) culture on RTS (Culture-RTS). The results were compared with a composite reference standard.

Results

A total of 126 cases with paired results were analysed. Against a composite reference standard, Ultra-RTS demonstrated the highest sensitivity (52%) and specificity (100%). Ultra-Stool showed 84.1% concordance with Ultra-RTS, demonstrating 45.5% sensitivity and 94.7% specificity (kappa = 0.65, 95% CI= 0.51–0.79). The sensitivity of Ultra-Stool was similar to Mtb culture (45.5%, p = 1.000) and higher than AFB-RTS (27.3%, p < 0.05). Assay positivity was associated with age and infiltration range in chest imaging.

Conclusions

When RTS is difficult to obtain, stool sample-based Ultra is a comparable alternative.

Le texte complet de cet article est disponible en PDF.

Keywords : Xpert MTB/RIF Ultra, Tuberculosis, Children, Trace-positive, Stool


Plan


© 2020  The British Infection Association. Publié par Elsevier Masson SAS. Tous droits réservés.
Ajouter à ma bibliothèque Retirer de ma bibliothèque Imprimer
Export

    Export citations

  • Fichier

  • Contenu

Vol 82 - N° 1

P. 84-89 - janvier 2021 Retour au numéro
Article précédent Article précédent
  • Methicillin-susceptible staphylococcus aureus in community-acquired pneumonia: Risk factors and outcomes
  • Catia Cilloniz, Cristina Dominedò, Albert Gabarrús, Carolina Garcia-Vidal, José Becerril, Diego Tovar, Estela Moreno, Juan.M. Pericás, Carmen Rosa Vargas, Antoni Torres
| Article suivant Article suivant
  • Presentations and outcomes of central nervous system TB in a UK cohort: The high burden of neurological morbidity
  • Clare Logan, Claire Mullender, Miriam Mirfenderesky, Nicholas Feasey, Catherine Cosgrove, Peter Riley, Angela Houston, Tom Harrison, Tihana Bicanic, Phil Rich, Paul Hart, Síle F Molloy, Derek C. Macallan

Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.

Déjà abonné à cette revue ?

Mon compte


Plateformes Elsevier Masson

Déclaration CNIL

EM-CONSULTE.COM est déclaré à la CNIL, déclaration n° 1286925.

En application de la loi nº78-17 du 6 janvier 1978 relative à l'informatique, aux fichiers et aux libertés, vous disposez des droits d'opposition (art.26 de la loi), d'accès (art.34 à 38 de la loi), et de rectification (art.36 de la loi) des données vous concernant. Ainsi, vous pouvez exiger que soient rectifiées, complétées, clarifiées, mises à jour ou effacées les informations vous concernant qui sont inexactes, incomplètes, équivoques, périmées ou dont la collecte ou l'utilisation ou la conservation est interdite.
Les informations personnelles concernant les visiteurs de notre site, y compris leur identité, sont confidentielles.
Le responsable du site s'engage sur l'honneur à respecter les conditions légales de confidentialité applicables en France et à ne pas divulguer ces informations à des tiers.


Tout le contenu de ce site: Copyright © 2024 Elsevier, ses concédants de licence et ses contributeurs. Tout les droits sont réservés, y compris ceux relatifs à l'exploration de textes et de données, a la formation en IA et aux technologies similaires. Pour tout contenu en libre accès, les conditions de licence Creative Commons s'appliquent.